High Levels of Urokinase-type Plasminogen Activator and Its Inhibitor PAI-1 in Cytosolic Extracts of Breast Carcinomas Are Associated with Poor Prognosis

Cancer Research

Volumn 53, Issue 11, 1993, Pages 2513-2521

  Mouridsen, Henning T ^c   Blichert Toft, Mogens ^c   Brnner, Nils ^a   Danø, Keld ^a  

^a FINSEN LABORATORY   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c Danish Breast Cancer Cooperative Group   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CYCLOPHOSPHAMIDE; FLUOROURACIL; LEVAMISOLE; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TAMOXIFEN; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; CYTOSOL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; PLASMINOGEN ACTIVATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYTOSOL; FEMALE; HUMAN; MENOPAUSE; MIDDLE AGE; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0027223048     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Dan⊘, K., Andreasen, P.A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L.S., and Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44: 139-266, 1985.
2. Blasi, F., Vassalli, J.D., and Dane, K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol., 104: 801-804, 1987.
3. Liotta, L.A., Steeg, P.S., and Stetler-Stevenson, W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
4. Pöllänen, J., Stephens, R.W., and Vaheri, A. Plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res., 57: 273-382, 1991.
5. Petersen, L.C., Lund, L.R., Nielsen, L.S., Dane, K., and Skriver, L. One-chain urokinase-type plasminogen acitvator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. Biol. Chem., 263: 11189-11195, 1988.
6. Andreasen, P.A., Georg, B., Lund, L.R., Riccio, A., and Stacey, S.N. Plasminogen activator inhibitors: hormonall y regulated serpins. Mol. Cell. Endocrinol., 68: 1-19, 1990.
7. Ellis, V., Pyke, C., Eriksen, J., Solberg, H., and Daño, K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann. N.Y. Acad. Sei., 667: 13-31, 1992.
8. Murphy, G., Ward, R., Gavrilovic, J., and Atkinson, S. Physiological mechanisms for metalloproteinase activation. In: H. Birkedal-Hansen, Z. Werb, H. Welgus, and H. Van Wart (eds.), Matrix Metalloproteinases and Inhibitors, pp. 245-255. Stuttgart: Gustav Fischer Verlag, 1992.
9. Sato, Y., and Rifkin, D.B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-ßrlike molecule by plasmin during co-culture. J. Cell Biol., 109: 309-315, 1989.
10. Ossowski, L., and Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35: 611-619, 1983.
11. Mignatti, P., Robbins, E., and Rifkin, D.B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47: 487-498, 1986.
12. Ossowski, L., Clunie, G., Masucci, M.T., and Blasi, F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol., 115: 1107-1121, 1991.
13. Skriver, L., Larsson, L.I., Kielberg, V., Nielsen, L.S., Andresen, P.B., Kristensen, P., and Dan⊘, K. Immunocytochemical localization of urokinase-type plasminogen - tivator in Lewis lung carcinoma. J. Cell Biol., 99: 753-758, 1984.
14. Grendahl-Hansen, J., Ralfkar, E., Kirkeby, L., Kristensen, P., Lund, L.R., and Dan⊘, K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in man. Am. J. Pathol., 138: 111-117, 1991.
15. Pyke, C., Kristensen. P., Ralfkacr, E., Gr0ndahl-Hansen, J., Eriksen, J., and Dane, K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol., 138: 1059-1067, 1991.
16. Pyke, C., Kristensen, P., Ralfksr, E., Eriksen, J., and Dan⊘, K. The plasminogen activator system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res., 51: 4067-4071, 1991.
17. Pyke, C., Ralfkser, E., Tryggvason, K., and Daño, K. Messenger RNA for two type IV collagenases is located in non-malignat stromal cells in human colon cancer. Am. J. Pathol., 142: 359-365. 1993.
18. Duffy, M.J., O'Grady. P., Devaney, D., O'Siorain, L., Fennelly, J.J., and Lijnen, H.J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer (Phila.), 62: 531-533, 1988.
19. Duffy, M.J., Reilly, D., O'Sullivan, C., O'Higgins, N., Fennelly, J.J., and Andreasen, P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50: 6827-6829, 1990.
20. Jänicke, F., Schmitt, M., Hafter, R., Hollrieder, A., Babic, R., Ulm, K., Gössner, W., and Graeff, H. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4: 69-78, 1990.
21. Jänicke, F., Schmitt, M., and Graeff, H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemostasis, 17: 303-332, 1991.
22. Thorpe, S.M. Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays. Breast Cancer Res. Treat., 9: 175-189, 1987.
23. Andersen, K.W., and Mouridsen, H.T. Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol. (Stockh.), 27: G21-(A1, 1988.
24. Bloom, H.J.G., and Richardson, W.W. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer, ll: 359-377, 1957.
25. Rosenquist, C., Thorpe, S.M., Dane, K., and Grendahl-Hansen, J. Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res. Treat., in press, 1993.
26. Cox, D.R. Regression models and life tables (with discussion). J.R. Statist. Soc., 187: 187-220, 1972.
27. Dixon, W.J. BMDP Statistical Software. Los Angeles: University of California Press, 1985.
28. Nielsen, L.S., Kellerman, G.M., Behrendt, N., Picone, R., Dane, K., and Blasi, F. A 55, 000-60, 000 Mr receptor protein for urokinase-type plasminogen activator: identification in human tumor cell lines and partial purification. J. Biol. Chem., 263: 2358-2363, 1988.
29. Pyke, C., Gram, N., Ralfkiar, E., Renne, E., Heyer-Hansen. G., Brünner, N., and Dane. K. The receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res., 53: 1911-1915, 1993.
30. Heyer-Hansen, G., Renne, E., Solberg, H., Behrendt, N., Plough, M., Lund, L.R., Ellis, V., and Dane, K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand binding domain. J. Biol. Chem., 267: 18224-18229, 1992.
31. Reilly, D., Christensen, L., Duch, M., Nolan, N., Duffy, M.J., and Andreasen. P.A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer, 50: 208-214, 1992.
32. Reich, E. Activation of plasminogen: a general mechanism for producing localized extracellular proteolysis. In: R.D. Berlin, H. Hermann, I.H. Lepow, and M.J. Tanzer (eds.). Molecular Basis of Biological Degradative Processes, pp. 155-169. New York: Academic Press, 1978.
33. Ellis, V., Wun, T.C., Behrendt, N., Renne, E., and Dane, K. Inhibition of receptor-bound urokinase by plasminogen activator inhibitors. J. Biol. Chem., 265: 9904-9908. 1990.
34. Andreasen, P.A., Nielsen, L.S., Kristensen, P., Grendahl-Hansen, J., Skriver, L., and Dane, K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J. Biol. Chem., 261: 7644-7651, 1986.
35. Kristensen, P., Pyke, C., Lund, L.R., Andreasen, P.A., and Dane, K. Plasminogen activator inhibitor type 1 in Lewis lung carcinoma. Histochemistry, 93: 559-566, 1990.
36. Cubellis, M.V., Wun, T.C., and Blasi, F. Receptor-mediated internalization and degradation of urorkinase is caused by its specific inhibitor PAI-1. EMBO J., 9: 1079-1085, 1990.
37. Montesano, R., Pepper, M.S., Mohlesteinlein, U., Risau, W., Wagner, E.F., and Orci, L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T-oncogene. Cell, 62: 435-445, 1990.
38. Weidner, N., Semple, J.P., Welch, W.R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
39. Harris, J.R., Candios, G.P., Hellman, S., and Fisher, B. Cancer of the breast, in: V. T De Vita, Jr., S. Hellman, and S.A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Vol. 2, pp. 1119-1177. Philadelphia: J.B. Lippincott Co., 1985.
40. Thorpe. S.M., Rochefort, H., Garcia, M., Freiss, G., Christensen, I.J., Khalaf, S., Paolucci, F., Pau, B., Rasmussen, B.B., and Rose, C. Association between high concentrations of Mr 52, 000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res., 49: 6008-6014, 1989.
41. Tandon, A.K., Clark, G.M., Chamnes, G.C., Chirgwin, J.M., and McGuire, W.L. Cathpepsin D and prognosis in breast cancer. N. Engl. J. Med., 322: 297-302, 1990.
42. Umehara, Y., Kimura, T., Yoshida, M., Oba, N., and Harada, Y Relationship between plasminogen activators and stomach carcinoma stage. Acta Oncol. (Stockh.), 50: 815-818, 1991.
43. Oka, T., Ishida, T., Nishino, T., and Sugimachi, K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinomas. Cancer Res., 51: 3522-3525, 1991.